Business Context and Reporting Period
Company: Arvinas, Inc. (ARVN)
Filing Type: Form 8-K (Current Report)
Date of Report: October 24, 2025
Event: Disclosure of preclinical data for ARV-806, a PROTAC KRAS G12D degrader, presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Triple Meeting).
Key Financial Metrics
This filing is a current report regarding scientific data and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Scientific Highlights
The primary material event is the announcement of preclinical data for ARV-806, designed to target both ON and OFF forms of KRAS G12D. Key findings include:
- Potency: In vitro degradation of KRAS G12D with picomolar potency across pancreatic, colorectal, and lung cancer cell lines without affecting wild-type or other mutant RAS isoforms.
- Comparative Advantage: Demonstrated >25-fold greater potency in reducing cancer cell proliferation and >40-fold higher potency in degrading KRAS G12D protein compared to clinical-stage competitors.
- Pharmacodynamics: Following a single intravenous dose in a colorectal tumor model, >90% of KRAS G12D was degraded for seven days, with sustained suppression of c-MYC and induction of pro-apoptotic BIM for at least five days.
- Efficacy: Achieved ≥30% tumor volume reductions in pancreatic and colorectal cell line-derived xenograft models and a lung cancer patient-derived xenograft model.
- Pan-KRAS Data: Oral pan-KRAS degraders showed superior combination efficacy with immune checkpoint blockade (7 complete responses) compared to a pan-RAS ON inhibitor (2 complete responses).
Guidance, Outlook, and Risks
Outlook: The Company is currently evaluating ARV-806 in a Phase 1 clinical trial for patients with KRAS G12D-mutated advanced solid tumors. Management believes the sustained pharmacodynamic activity supports intermittent clinical dosing.
Risks and Contingencies: The filing contains forward-looking statements regarding the potential of ARV-806 to address unmet needs and become a best-in-class therapy. Actual results may differ materially due to risks discussed in the Company's quarterly and annual reports. The Company assumes no obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the specific design and enrollment status of the ongoing Phase 1 clinical trial for ARV-806.
- Review the full text of the press release (Exhibit 99.1) for detailed methodology of the preclinical studies.
- Assess the competitive landscape for KRAS G12D inhibitors and degraders to contextualize the reported potency advantages.
- Monitor upcoming regulatory filings for any updates on the Phase 1 trial timeline or safety data.
- Confirm the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.